Tocqueville Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Tocqueville Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$563K	Sell	2,300 -1,900	-45%	-$412K	0.01%	426
2026 Q1	$710K	Sell	4,200 -200	-5%	-$34.5K	0.01%	399
2025 Q4	$804K	Sell	4,400 -1,250	-22%	-$175K	0.01%	401
2025 Q3	$686K	Buy	5,650 +450	+9%	+$50.7K	0.01%	400
2025 Q2	$543K	Hold	5,200	–	–	0.01%	411
2025 Q1	$606K	Buy	5,200 +250	+5%	+$28.5K	0.01%	390
2024 Q4	$419K	Sell	4,950 -150	-3%	-$13.8K	0.01%	441
2024 Q3	$458K	Sell	5,100 -100	-2%	-$8.73K	0.01%	415
2024 Q2	$419K	Sell	5,200 -1,100	-17%	-$81.4K	0.01%	422
2024 Q1	$503K	Sell	6,300 -400	-6%	-$33.6K	0.01%	408
2023 Q4	$533K	Buy	6,700 +500	+8%	+$33.4K	0.01%	389
2023 Q3	$433K	Sell	6,200 -1,000	-14%	-$74.8K	0.01%	415
2023 Q2	$517K	Hold	7,200	–	–	0.01%	410
2023 Q1	$444K	Hold	7,200	–	–	0.01%	421
2022 Q4	$555K	Buy	7,200 +100	+1%	+$5.98K	0.01%	430
2022 Q3	$317K	Buy	+7,100	New	+$355K	0.01%	507
2020 Q3	–	Sell	-2,500	Closed	-$206K	–	651
2020 Q2	$206K	Buy	+2,500	New	+$192K	﹤0.01%	622

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tocqueville Asset Management's AXSM Position: Q2 2026 in Review

Tocqueville Asset Management reduced its Axsome Therapeutics (AXSM) stake by 45% in Q2 2026, selling an estimated $412K and leaving 2,300 shares worth $563K. The position accounts for 0.01% of the portfolio, ranked #426.

Tocqueville Asset Management first reported a position in AXSM in Q2 2020 and has held it in 17 quarters since. The position peaked at $804K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Tocqueville Asset Management held 2,300 shares of Axsome Therapeutics worth $563K as of Q2 2026.
Tocqueville Asset Management sold 1,900 Axsome Therapeutics shares in Q2 2026, an estimated $412K.
Axsome Therapeutics made up 0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #426 holding.
Tocqueville Asset Management first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 17 quarters since.
Tocqueville Asset Management's Axsome Therapeutics position peaked at $804K in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.